AH CONT'D

a. isolating immune cells from an individual organism;
b. introducing target cells to said immune cells;
c. adding a substrate to said target and said immune cells, said substrate having a structure which changes via cell interactions;
d. determining a base activity of a mixture of said immune cells, said target cells, and said substrate using a spectrometer;
e. adding a first xenogenic pharmaceutical product to said mixture following step d;
f. measuring a reaction activity of said mixture following step e;
g. comparing said reaction activity to said base activity;
h. analyzing step g to determine at least one of a tolerance and effectiveness of said first product for said individual organism;
i. repeating steps a through g using a second xenogenic pharmaceutical product should step h produce undesirable effects; and
j. comparing said first and said second products, if step i is executed, to determine an optimal effectiveness and tolerance of possible alternative xenogenic pharmaceutical products available for selection for said individual organism.

10. The method of claim 9, wherein said xenogenic pharmaceutical product is selected from the group consisting of homoeophatic active substances, natural products of plant, animal and bacterial origin and mixtures of active substances.

11. The method of claim 9, wherein said target cells comprise cancer cells.

12. The method of claim 9, wherein said target cells comprise virus-infected cells.

13. The method of claim 9, wherein said target cells [compared] one of normal cells, allogenic cells, autogenic cells and xenogenic cells.

14. The method of claim 9, wherein said substrate comprises a tetrazolium salt.